Skip to main content
. 2021 Jul 29;21(3):273–283. doi: 10.1007/s40268-021-00357-0

Fig. 5.

Fig. 5

In vitro validation of the inhibitory effect of the 13-amino acid peptide inhibitor (13AApi) on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike receptor-binding domain (RBD) was examined with an enzyme-linked immunosorbent assay (ELISA) test kit. A The image reproduced from the BP Biosciences ELISA kit demonstrates the steps in the assay. B Percent inhibitory activity of the 13AApi at the indicated concentrations on the binding of SARS-CoV-2 spike RBD to angiotensin-converting enzyme 2 (ACE2). The plotted graph represents the mean of three biological replicates